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S u m m a r y  
 
Aging of population becomes an emerging health 
problem nowadays. One of symptoms of societal aging is an 
observed significant increase in the rate of dementia, which 
gradually excludes large group of patients from every aspect 
of life. Magnetic resonance imaging (MRI) is one of the most 
rapidly developing methods of neuroimaging. Modern MR 
techniques not only present structure and function of the 
brain, but also allow to assess metabolism, microcirculation 
and integrity if nervous tissue at the cellular level. The paper 
presents opportunities and perspectives of MRI in the 
diagnostics and differentiation  of dementia. 
 
 
S t r e s z c z e n i e  
 
Starzenie się populacji staje się coraz bardziej aktualnym 
problemem zdrowotnym naszych czasów. Jednym z prze-
jawów starzenia się społeczeństwa jest obserwowany istotny 
wzrost częstości zespołów otępiennych i związane z tym 
stopniowe wyłączanie dużej grupy chorych z każdego 
aspektu życia. Badanie metodą rezonansu magnetycznego 
(MR) jest jedną z najszybciej rozwijających się metod 
obrazowania mózgu. Współczesne techniki MR stwarzają nie 
tylko możliwość oceny zmian strukturalnych i czynnoś-
ciowych, ale również metabolizmu, mikrokrążenia i integral-
ności tkanki nerwowej na poziomie komórkowym. Praca 
przedstawia możliwości i perspektywy badania MR w diag-
nostyce i różnicowaniu zespołów otępiennych.  
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General improvement of living conditions and 
better health care systems resulted in a longer mean life 
span. Aging of the population is a significant social 
and medical problem of our times. It is estimated that 
in 1900, 1% of world population accounted for 
individuals over 65 years of age. In 1992 that 
percentage rate increased to 6.2% and according to 
prognoses, will reach as much as 20% in 2050  [1]. 
One of the symptoms of aging population is the 
witnessed   significant  increase  in  the  incidence  of 
 
 
dementia syndromes resulting in progressive exclusion 
of a large group of patients from every aspect of life. 
That is why the problem of advanced-age diseases is 
connected with increasing interest of researchers and 
also politicians (e.g. the document of the European 
Council from 2008, entitled Council Conclusions on 
public health strategies to combat neurodegenerative 
diseases associated with aging and in particular 
Alzheimer's disease). 
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The main objectives of the research on 
degenerative syndromes of the elderly include 
searching for biomarkers,  i.e. indicators or symptoms 
allowing early and reliable diagnosis of dementia. 
These may include aberrations in psychological tests, 
laboratory indicators or specific features of the brain 
that can be detected in imaging studies.  
Searching for biomarkers of dementia focuses on 
such currently used imaging techniques as PET 
(positron emission tomography) and MRI (magnetic 
resonance imaging). The PET examinations, due to 
their limited accessibility, high price and exposition to 
ionizing radiation, seem to have less chance for a broad 
clinical use. Therefore, most examinations focus on the 
diagnostics of dementia with the use of MRI being a 
method that allows evaluation of brain morphology, 
chemical composition, ongoing metabolic processes 
and function. The aim of this work was to present 
possibilities and perspectives of the use of MRI in 





According to the definition of WHO, dementia 
syndrome is a set of symptoms caused by brain 
disease, usually a chronic or progressive one, clinically 
characterized by numerous disorders of higher cortical 
functions such as memory, thinking, orientation, 
reasoning, counting, ability to learn, language, and 
evaluation [1]. Moreover, disturbances of cognitive 
functions are frequently accompanied or even preceded 
by emotional, behavioral and motivational disorders. A 
more precise definition is given by DSM-IV 
(Diagnostic and Statistical Manual-American 
Psychiatric Association), which defines dementia as a 
set of symptoms of disturbed cognitive processes 
including, apart from disturbed memory, deficits of at 
least two functions from the following: speech 
(aphasia), voluntary complex movement (apraxia), 
ability to discriminate and identify objects (agnosis), as 
well as inability to plan, initiate, control and correct 
complex behaviors (disturbed executive functions) [2]. 
Moreover, cognitive deficits should be serious enough 
to disturb professional activity, social functioning and 
execution of everyday activities. 
It seems that dementia is not a normal process of 
body aging. It can result from over 50 pathologies 
which cause primary or secondary disorders of the 
central nervous system (CNS). To systematize the 
background of the problem, we may distinguish 6 main 
etiological groups in the literature: vascular, 
degenerative, metabolic, infectious, toxic, and CNS 
injuries. The statistics and demographic data clearly 
show that the incidence rate of dementia is determined 
by age, i.e. the increasing rate of elderly individuals in 
the population is directly connected with increased 
incidence of dementia. Studies have shown that among 
individuals between 65 and 85 years of age the 
incidence is the highest and the main 
neurodegenerative disease is the Alzheimer’s disease, 
and among individuals over 85 y.o.a., the vascular 
dementias are the most prevalent [3, 4]. 
The most numerous group includes vascular and 
degenerative dementias. The remaining conditions, 
although sporadic, require insightful differential 
diagnostics, as they are potentially reversible. In 
Europe, the dominant form of dementia is the 
Alzheimer’s disease (AD), accounting for 50-60% of 
all cases. It is followed by DLB dementia (dementia 
with Lewy bodies) and VaD (vascular dementias)  
[3, 4]. 
The Alzheimer’s disease is a degenerative disease 
of the CNS, with progressive deficits of cognitive 
function and cortical disturbances – apraxia, aphasia, 
memory and behavior disorders, and psychotic 
symptoms. Early phase of AD reveals non-specific 
symptoms with dominant disturbances of memory. The 
disease is strictly age-determined. In individuals aged 
between 65 and 85 years, the incidence doubles every 
5 years [4]. People with advanced AD are not able to 
function independently in their everyday life.  
Dementia with Lewy bodies is characterized by 
cognitive disturbances with features of Parkinson’s 
disease of changing type with delusions and 
hallucinations. Typical for this disease is 
hypersensitivity reaction and poor response to 
neuroleptics. The accompanying symptoms include 
syncope, repeated falls and transient  disturbances of 
consciousness [5, 6]. 
Vascular dementia reveals a picture typical for 
subcortical disturbances: memory disturbances, 
changes of emotions and personality, executive 
function disturbances and slower information 
processing. Usually, these symptoms result from 
numerous minor strokes. Risk factors of VaD include 
mainly age, diabetes, atherosclerotic lesions of internal 
carotid, vertebral and cerebral arteries, 
hypercholesterolemia and stroke in past [7].       
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Diagnostics of dementia underscores 4 basic 
clinical features of the disease: the profile of cognitive 
disturbances, the onset and time sequences of 
appearing clinical symptoms, psychopathological 
disorders (psychotic syndromes and disturbed 
behaviour) and neurological symptoms [8]. These 
components are included in detailed criteria 
differentiating VaD from degenerative diseases of the 
brain. A thorough analysis of criteria of dementia 
supported by advanced MR imaging facilitates the 
proper diagnosis. 
 
DEMENTIA SYNDROMES IN IMAGING STUDIES 
– CURRENT IMAGING PRACTICES 
 
The main symptom of brain degenerative diseases 
includes disturbed cognitive functions. It is estimated 
that in half of the patients suffering from dementia, the 
disease was not diagnosed and according to NDS 
(National Dementia Strategy), dementia is diagnosed 
too late and too rare. Development of neuroimaging 
techniques facilitates clinical diagnosis of dementia, 
mainly by excluding the organic causes of brain 
disorders. Imaging methods used in the diagnostics of 
dementia may be divided into structural (CT, 
morphological MRI with volumetry, Doppler 
ultrasonography) and functional: evaluation of 
diffusion, diffusion tensor in MRI, evaluation of 
perfusion with MRI and CT, functional magnetic 
resonance (fMRI), as well as SPECT, i.e. single-photon  
emission computed tomography, and PET. 
Owing to the availability of CT, this is frequently 
the first examination performed in a patient with 
dementia or suspected dementia. However, it should be 
remembered that its diagnostic capabilities are quite 
limited and the examination detects only some 
pathological lesions typical for dementia. In CT it is 
easy to evaluate brain atrophy (cortical, subcortical or 
mixed). Their location may suggest the type of 
dementia, e.g. AD-related atrophy of hippocampal area 
mostly, FTD-related atrophy of frontal and temporal 
lobes, subcortical atrophy in Hintington’s disease and 
atrophy of frontal lobes and cerebellum in alcoholic 
dementia [9]. The evaluation of the degree of atrophy 
may be susceptible for subjective impreciseness of 
assessment, however linear measurements (Huckmann 
number, the width of the III ventricle, the width of 
lateral cerebral fissures) or evaluation of the volume of 
intracranial fluid spaces allow for fairly accurate 
tracking of neurodegenative changes over time. The 
degree of atrophy should be evaluated regarding the 
age of the patient. Moreover, an important advantage 
of atrophy evaluations is the possibility of a precise 
control of dementia changes in time [9]. 
Over the past years, morphological imaging of 
dementia with MRI has gained on importance. This 
tendency results from a higher contrast resolution of 
MRI as compared to CT, which enables precise 
evaluation of particular structures of the brain, e.g. 
hippocampus, typically undergoing atrophy in AD, or 
the gray matter of the hemispheres selectively. 
Increased interest in dementia imaging with this 
method was a result of studies carried out by Award et 
al. [9, 10]. They showed that in MRI images of the 
studied patients, the incidence of lesions in the white 
matter reaches 22% in a group below 40 years of age, 
51% among individuals aged 41-60, and 92% among 
individuals over 60 y.o.a. To compare with, CT detects 
focal lesions in 7% of individuals aged 55 – 69 years, 
and in less than 1% of individuals under the age of 45 
[10]. The advantage of MRI over CT is also visible in 
the evaluation of ischemic lesions. This follows from a 
significantly higher sensitivity of T2-weighted images 
in detecting small ischemic lesions within basal 
ganglia, white matter, brain stem, and cerebellum. 
Specific MRI image allows also for diagnosing rare 
neurodengenerative diseases, such as Hallevorden-
Spatz syndrome, Wilson or Creutzfeldt-Jakob disease 
[9]. 
 





VBM morphometry is a measurement of volume 
of the grey matter, comparing signal intensity within 
particular pixels of an image of a selected anatomical 
structure of the brain. The measurement of the volume 
of tissue structures or fluid spaces is carried out at sites 
strategic for a given type of dementia. On the basis of 
information thus received it is possible to evaluate the 
advancement of the disease as well as clinical 
prognosis of disease progression [9, 11]. 
However, it should be remembered that due to 
inter-individual variability of the size of the skull as 
well as insufficient specificity, the value of single 
linear measurements in the diagnostics of CT imaging 
may raise doubt. MRI imaging is characterized by high 
accuracy in volume evaluation – up to 0.1 cm
3
. Such a 
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precision in measurements guarantees high 
repeatability and sensitivity of the method [10]. In case 
of high-resolution MRI imaging, software packages 
required for data processing generate planimetric and 
volumetric measurements. Planimetric measurements 
are obtained with area segmentation technique. This 
method uses the difference in signal intensity between 
the brain cortex, subcortical structures and the white 
matter [11]. Values obtained in such a way are 
normalized with regard to so called total intracranial 
volume [11]. The evaluation is made with the use of 
semi-automatic technique. 
In order to obtain images, the IR (inversion 
recovery) sequences are used or typical T2-weighted 
images, in FSE (fast spin echo) sequence. 
Examinations with the use of VBM showed that in AD 
there is not only a typical atrophy of structures of the 
superior-medial part of the temboral lobes, but also 
atrophy within the insular cortex and caudate nuclei 
[11, 12]. 
Jack et al. [13] in their logitudinal studies showed 
that in the group of study patients with diagnosed AD 
and healthy, elderly individuals, a higher index of 
hippocampal atrophy was found in patients with AD 
(4-6% a year). A similar interrelation was also shown 
for the entorhineal cortex [13]. This finding 
acknowledge volumetric measurements of the 
entorhineal cortex as dedicated indicator of clinical 
deterioration in patients with AD [14]. For evaluation 
of progression of brain atrophy, it is recommended to 
use a method which allows for “superimposition” of 
subsequent images and subtraction of the baseline 
image. As a result, the acquired image will include 
marked in color (usually red) areas of brain atrophy 
[11]. 
Magentic Resonance Spectroscopy (MRS) in the 
literature called „window for tissue metabolism”. In 
MRS it is possible to non-invasively assess the amount 
of selected chemical compounds in tissues and 
indirectly draw conclusions on metabolism or cellular 
integrity of the examined area [15]. The spectroscopy 
uses signals of chemical compounds including nuclides 
not only 1H but also 13C, 19F,31P,15N and 23Na. The 
result of the test is the resonance spectrum of the tested 
sample, shown in coordinates. The spectrum results 
from converting signals of free precession FID 
registered within a selected area. 
The most frequently used method of localization is 
the SVS (single voxel sptectroscopy). It allows to 
ascribe a different resonance frequency to every 
examined area. Undoubtedly, the advantage of this 
method is high homogeneity of the study area, short 
examination time (4-8 min), high signal-to-noise ratio 
and easiness in selective attenuation of water signal. 
Other localization methods include ISIS (Image-
selected in vivo spectroscopy), PRESS (point-resolved 
localized spectroscopy) and STEAM (Stimulated echo 
acquisition mode). Differences between them involve 
changing RF impulse and coordinates of time 
sequences [10]. We should also mention the 
MultiVoxel technique. It allows for chemical shift 
imaging (CSI) and allows for simultaneous registration 
of signal from a few adjacent voxels. The acquired 
image is a map of selected metabolites with their 
spatial position in the examined layer of the organ  
[10, 16]. 
MRS has long been applied in studies on dementias 
[9]. Proton spectroscopy is the most frequently used 
one (hydrogen, 1HMRS). More rarely used, mainly 
due to equipment requirements, are phosphorus 
spectroscopy (31PMRS), fluorine spectroscopy 
(19FRS) and carbon spectroscopy (13CMRS). The 
1HMRS allows for testing the following brain 
metabolites: NAA (N-acetylaspartate), choline and its 
metabolites, myoinositol, creatinine and creatinine 
phosphorane, as well as the glutamate-glutamine 
complex. NAA in immature oligodendrocytes is found 
mostly intracellularly. Thus, it is held for a marker of 
neuronal density and as an indicator of metabolic 
activity of nervous cells [15, 17] and NAA decrease is 
connected with neuronal atrophy [18]. In a normal 
spectroscopic image of the brain, it shows the highest 
peak. 
MRS creates new possibilities of diagnostics of AD 
in living individuals. A typical picture of AD is as 
follows: lower NAA concentration, higher myoinositol 
concentration [9, 10]. Intensification of lesions is 
especially significant in associative centers. In a test 
differentiating healthy middle-aged individuals and 
patients with AD, MRS showed sensitivity of 83% and 
specificity of 98%. In a test differentiating AD and 
other forms of dementia, MRS showed specificity of 
64% and sensitivity of 82% [10]. 
In case of dementia with Lewy bodies, diagnostics 
with spectroscopy has been incidental so far. The 
reason was technical problems which can appear 
during the examination (parkinsonism, no cooperation 
of the patient and fluctuations of cognitive functions). 
So far, the first and the largest project aimed at 
spectroscopic examination in DLB was the study by 
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Molina et al. [18]. It included 12 patients meeting the 
criteria for DLB. All included individuals had 
fluctuations of cognitive functions, visual 
hallucinations, and parkinsonism. The authors tried to 
evaluate brain metabolites in the temporal lobes and 
basal ganglia but the examination of the mentioned 
areas ended in failure due to no homogeneity of the 
brain in those areas. Significant differences in the 
concentration of metabolites between DLB and the 
control group were found only in the white matter. 
Diffusion tensor imaging (DTI) is a technique of 
MRI used to visualize the course and to evaluate the 
integrity of the pathways of the white matter. DTI is an 
advanced diffusion technique which, apart from 
quantitative evaluation of free diffusion of water in the 
extracellular space of living tissues, expressed as MD 
(mean diffusivity) allows also for qualitative and 
quantitative evaluation of the direction of diffusion 
[17]. 
A natural barrier for free diffusion in the tissues of 
the cerebral and spinal white matter is the cell 
membrane and myelin sheath of axons. This is where 
the movement of water particles is limited and 
anisotropic – it is expressed by limited diffusion in 
perpendicular directions with regard to the white 
matter fibers. The degree of diffusion anisotropy is 
shown by FA (fractional anisotropy) parameter. FA is 
also called an index of white matter integrity [11]. A 
decrease in its value signals damage and degradation of 
white matter pathways or widening of the extracellular 
space in the course of vasogenic edema [19]. An 
additional option of DTI is tractography of diffusion 
tensor. This method visualizes in 3D the anisotropy of 
water diffusion in the white matter, which corresponds 
to the course of white matter fibers. Tractography uses 
an algorithm of drawing the course of continuity of 
fibers from a chosen point. It should be remembered 
that the registered course of fibers is averaged for 
every voxel [11]. 
DTI is widely used in the evaluation of dementia 
disorders [9]. In dementia there is a secondary 
degeneration of the fibers of the white matter, probably 
due to Waller degeneration, which concerns the 
associative pathways (longitudinal upper and lower 
bundles, fronto-occipital bundles, and posterior part of 
the cingulum), callosal pathways (ganu and splenium 
corporis callosi) [9]. Sąsiadek et al. showed the highest 
lowering of FA within the posterior cingulum, with a 
strong difference between AD and mild cognitive 
impairment (MCI), and between MCI and healthy 
population. DTI performed in the area of the posterior 
cingulum was the best in differentiating those groups 
of patients, showing superiority over MRS and PWI 
(perfusion weighted imaging), or even PET [9].  
Functional MRI is a method presenting activation 
of the brain cortex in response to specific stimuli or at 
rest. The intensity of MRI signal is related to the 
degree of hemoglobin oxidation. Activation of neurons 
in response to a stimulus results in a decrease in 
oxyhemoglobin level in local microcirculation and 
increase of CO2 and deoxyhemoglobin level. As a 
result of autoregulation, the local blood flow rises after 
2-6 sec, which causes an increase in the amount of 
oxyhemoglobin and washout of the deoxygenated 
form. Both forms of hemoglobin present different 
magnetic properties, which causes a change in MR 
signal intensity of 1-5% in the BOLD technique [20]. 
fMRI has a high linear and temporal resolution. It is 
carried out in two phases. The first one is the 
morphological (structural) examination. Next, the areas 
of the brain cortex are subjected to a series of active or 
passive (stimulus removal) stimulation separated by 
periods of rest [11]. After comparing images of 
activation obtained in control situation of rest and task, 
a map of brain activity is obtained, correlated with the 
influence of a selected component [21]. 
The fMRI examination in case of cognitive disorders 
gains on its importance. An essential role is played by 
the possibility of comprehensive evaluation of 
structural changes and brain function [11]. 
Scientific research with the use of fMRI are usually 
conducted on good-cooperating volunteers. The results 
of neuropsychological or movement tests are much 
better in those individuals than in patients. Patients 
with dementia have their cognitive functions tested. 
Therefore, when preparing the paradigms – tasks – it is 
necessary not only to include neuropsychologist’s help 
but also to simplify stimuli adequately [11]. Cognitive 
testing of dementia is based on evaluation of working 
memory (remembering pictures, associating face with 
name), arithmetic functions (counting forward and 
backward, addition and subtraction), visual-spatial 
functions (comparing objects seen from different sides, 
identifying the angle between the arms of the clock) 
[10].  
In AD there is a decreased activity of the cortex 
during performance of cognitive tasks, especially in 
parietal lobes and hippocampus [9]. It was also shown 
that specific changes in fMRI appear even before the 
occurrence of clinical features typical for AD: 
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increased activity of the praecuneus and decreased 
activity within the middle part of temporal lobes and 
prefrontal cortex [10, 11]. One should remember that 
the area of increased or decreased activity would point 
to disturbances of interaction between certain centers 
and not to their damage [11].  
This method allows for an assessment of the 
influence of procognitive medications on memory 
functions during long-term therapy. Increased activity 
was found in the areas of the cortex stimulated during 
memorization [21]. fMRI may also be helpful in 
differentiating AD from other pathologies associated 
with dementia, e.g. the Parkinson’s disease, vascular 
dementia or fronto-temporal dementia [22]. In case of 
AD, it is extremely important to select patients at an 
early stage of the disease. AD is frequently preceded 
by the MCI. Distinguishing MCI patients with 
increased risk of development the AD is clinically 
challenging and fMRI seems to facilitate this.  
Perfusion-weighted imaging (PWI) permits 
evaluation of brain microcirculation on the basis of 
changes in MR signal intensity. Depending on the 
technique applied, PWI allows for quantitative and 
qualitative evaluation (color maps, regional blood flow 
(CBF), volume of blood in the vascular bed (CBV), 
and mean time of blood flow through microcirculation 
(MTT)). Examination of perfusion is used in detecting 
and differentiating the type of dementia and in 
monitoring of its progression.  
PWI can be performed with or without 
administration of contrast media. Perfusion 
examination without the use of gadolinium 
preparations is carried out with the ASL (Arterial Spin 
Labelling) method, i.e. marking of blood spins. This 
technique includes saturation or inversion of arterial 
blood spins at the level of the neck, and then their 
detection in the measured volume. The marked spins, 
moving to the vascular bed of the brain, change 
magnetization of brain tissues, which is registered as 
dynamic change in signal intensity [9, 10, 17]. The 
second method requires i.v. injection of paramagnetic 
contrast agents and is based on the evaluation of a 
simple change in relaxation time T1 or uses the effect 
of magnetic susceptibility of the bolus, and it 
influences the relaxation time T2 (DSC). DSC is a 
more precise method but requires repeated acquisition 
of data during the first pass of the bolus, and thus poses 
high requirements for the equipment [10]. 
MR perfusion is valuable method in differentiating 
VaD and AD [11].  It can be also used in monitoring 
the progression of dementia. Walecki et al. showed that 
there is a correlation between CBF and CBV 
proportional to the MMSE score [14]. Decreased 
perfusion in cortex indicate dementia [9]. Location of 
abnormalities seen in PWI in different forms of 
dementia correlates well with SPECT results [9]. 
According to Sąsiadek et al., the most intensified 
perfusion abnormalities in dementia can be found 
within the cingulate and this may be the cue for 
differentiating AD patient from MCI patient, and MCI 
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